Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic Wharton's jelly mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- Cell Therapy Center, University of Jordan
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic Wharton's jelly mesenchymal stromal cells (WJMSC) is an investigational cell therapy being developed by the University of Jordan for the treatment of autism spectrum disorder (ASD). Derived from the umbilical cord's Wharton's jelly, these mesenchymal stem cells are administered intravenously to leverage their immunomodulatory and neuroprotective properties. The therapy aims to mitigate neuroinflammation and immune system dysfunction, which are key components of ASD pathophysiology. By utilizing paracrine mechanisms and molecular-mediated neuroprotection, the treatment seeks to restore functional neurologic circuitry and improve core symptoms of ASD. It is currently being evaluated in a Phase 1 clinical trial (NCT06293950) to assess safety and efficacy in pediatric patients.
- Other names
- Wharton's jelly mesenchymal stem cellsWJ-MSCsallogeneic WJMSC
Beyond the preview
Go deeper on allogeneic Wharton's jelly mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic Wharton's jelly mesenchymal stromal cells.